Amity is a neuroscience-based company with a unique portfolio of product candidates and innovative platform technologies. Along with our strategic partners, we are dedicated to enhancing therapeutic benefits and addressing significant unmet needs in patient care.
Founded in early 2022 through a joint venture between Anshi Pharmaceuticals, Ranxin Health, and selected investors, Amity Therapeutics’ innovative business model focuses on identifying late stage products to commercialize in China. Amity was founded to license, develop, and commercialize product candidates for the broader central nervous system (CNS), including schizophrenia, ADHD, epilepsy and psychiatry. Our emphasis is on highly differentiated therapies that empower patients, care partners, and healthcare providers. The benefits of our unique pipeline allow us to form strategic partnerships with a wide variety of companies and academic institutions.
We seek to transform the lives of people in China who are suffering from
CNS & psychiatric diseases, including Parkinson’s disease, epilepsy,
schizophrenia, ADHD, bipolar disorder, and depression through
development of novel therapies.
We have built a highly experienced business development clinical,
registration, academic promotion, sales & distribution, and project
management team who combine a results-driven mindset with proven
expertise in the pharmaceutical industry.
